HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

CGC

Canopy Growth Corporation (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Hold 2.6 / 5 1 analysts
$0.95
$0.00 (-0.11%)
Target: $1.22 (29.0%)
Sign in to add CGC to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$425.41M
P/E Ratio (TTM)-
Forward P/E-7.93
EPS (TTM)$-0.62
Dividend Yield-
Profit Margin-92.38%
Revenue Growth9.60%
ROE-44.71%
Debt/Equity39.95
Recommendation Hold 2.6
Analyst Target$1.22
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)38.7
Beta2.41
SMA 20-
SMA 40-
52-Week High$2.38
52-Week Low$0.84
50-Day Avg$1.06
200-Day Avg$1.16
Avg Volume$9.72M
Volume$3.66M

Performance Analysis

NEUTRAL

CGC presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.84), which could present a value opportunity.
~ RSI at 38.7 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 9.6% year-over-year.
- Operating at a loss with -92.4% margin.
~ Wall Street consensus is "Hold" from 1 analysts.
+ Average analyst target of $1.22 implies 29.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:02 UTC

Back to Screener Export Report